Heartflow to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Heartflow (Nasdaq: HTFL) said company management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast and archived replay will be available on Heartflow's Investor Relations website at https://ir.heartflow.com.
The presentation will cover recent company developments and outlook for investors; timing and access details are provided for shareholders and analysts.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, HTFL gained 2.50%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: PRVA -0.47%, PINC +0.07%, BTSG +2.35%, HNGE -1.89%, WAY -5.05%. No clear sector-wide direction relative to HTFL’s -0.62% move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 18 | Clinical endorsement | Positive | +6.5% | ACC/AHA statements backing Heartflow Plaque Analysis prognostic value and pathway. |
| Dec 11 | Clinical & economic data | Positive | +1.0% | Large FFRCT analyses showing outcome prediction and per-patient cost savings. |
| Nov 19 | Investor conference | Neutral | -0.3% | Announcement of participation in Piper Sandler healthcare conference fireside chat. |
| Nov 12 | Earnings results | Positive | +4.6% | Q3 2025 revenue growth, strong gross margin, IPO cash and initial guidance. |
| Nov 03 | Conference data | Positive | -8.4% | AHA 2025 late-breaking AI plaque analysis and multiple abstracts announcement. |
HTFL has generally reacted positively to fundamental and validation news, while one major data-focused conference event showed a notable negative divergence.
Over the last few months, Heartflow reported strong Q3 2025 growth with revenue of $46.3 million and guidance of $173.0–$173.5 million, which was followed by a 4.59% gain. Subsequent clinical and guideline endorsements for its AI plaque and FFRCT analyses saw additional positive moves of 6.49% and 1%. Participation in prior investor conferences had minimal impact. Today’s J.P. Morgan conference appearance fits this pattern of routine investor-relations visibility rather than a new fundamental milestone.
Market Pulse Summary
This announcement highlights Heartflow’s participation in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, providing a platform for management to engage investors. It mirrors prior conference appearances that served mainly as visibility and communication events rather than new data catalysts. Investors may watch for any incremental commentary versus past disclosures, especially following recent clinical validations and Q3 2025 financial results with revenue of $46.3 million and strong growth.
Key Terms
coronary artery disease medical
AI-generated analysis. Not financial advice.
MOUNTAIN VIEW, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today announced that members of management will present at the upcoming 44th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, January 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET.
A live and archived version of the presentation will be available on the Investor Relations section of the Heartflow website at https://ir.heartflow.com.
About Heartflow’s Technology and Research
Heartflow’s technology is redefining precision cardiovascular care through clinically-proven AI and the world’s largest coronary imaging dataset. Heartflow has been adopted by more than 1,400 institutions globally and continues to strengthen its commercial presence to make this cutting-edge solution more widely available to an increasingly diverse patient population. Backed by American College of Cardiology and American Heart Association (ACC/AHA) guidelines and supported by more than 600 peer-reviewed publications, Heartflow has redefined how clinicians manage care for over 500,000 patients worldwide.1 Key benefits include:
- Proprietary data pipeline: Built from more than 160 million annotated CTA images, Heartflow’s data foundation powers advanced AI models that deliver highly accurate, reproducible insights across diverse patient populations.
- Extensive clinical and real-world validation: Heartflow’s AI-driven solutions have been validated through clinical evidence in over 100 studies assessing over 365,000 patients. Proven in real-world practice with reproducibility and accuracy, Heartflow’s coronary CTA image acceptance rates exceed
97% . - Seamless clinical integration via upgraded workflow: Heartflow delivers final quality-reviewed analyses instantly upon order, enabling clinicians to move from diagnosis to decision without delay.
- Quality system, global security and patient-data integrity compliance: Heartflow meets or exceeds leading international standards, including HITRUST, SOC 2 Type 2, ISO 13485, and ISO 27001.
About Heartflow, Inc.
Heartflow is transforming coronary artery disease from the world’s leading cause of death into a condition that can be detected early, diagnosed accurately, and managed for life. The Heartflow One platform uses AI to turn coronary CTA images into personalized 3D models of the heart, providing clinically meaningful, actionable insights into plaque location, volume, and composition and its effect on blood flow — all without invasive procedures. Discover how we’re shaping the future of cardiovascular care at heartflow.com.
Investor Contact
Nick Laudico
nlaudico@heartflow.com
Media Contact
Elliot Levy
elevy@heartflow.com
____________________
1 Gulati, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation & Diagnosis of Chest Pain. J Am Coll Cardiol.
FAQ
When will Heartflow (HTFL) present at the J.P. Morgan Healthcare Conference?
How can investors watch Heartflow's (HTFL) J.P. Morgan presentation?
What topics will Heartflow (HTFL) cover at the January 13, 2026 presentation?
Will Heartflow (HTFL) provide a replay of the J.P. Morgan presentation?
What time is Heartflow's presentation for East Coast investors?
Where can analysts find supporting materials for Heartflow's (HTFL) conference presentation?
